Mark Breidenbach
Stock Analyst at Oppenheimer
(1.72)
# 2,940
Out of 4,817 analysts
59
Total ratings
31.15%
Success rate
-0.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $10.57 | +183.82% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.43 | +812.28% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.77 | +860.45% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $8.75 | +985.71% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.37 | +1,724.82% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.77 | +1,196.51% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.37 | +3,104.27% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.92 | +5,379.45% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.40 | +400.00% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $0.80 | +3,886.05% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $3.08 | +387.01% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.06 | +11,219.69% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.25 | +779,900.00% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $3.90 | +69,130.77% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $10.57
Upside: +183.82%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.43
Upside: +812.28%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.77
Upside: +860.45%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $8.75
Upside: +985.71%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.37
Upside: +1,724.82%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.77
Upside: +1,196.51%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.37
Upside: +3,104.27%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.92
Upside: +5,379.45%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.40
Upside: +400.00%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $0.80
Upside: +3,886.05%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.08
Upside: +387.01%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.06
Upside: +11,219.69%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.25
Upside: +779,900.00%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $3.90
Upside: +69,130.77%